211 related articles for article (PubMed ID: 37730692)
1. Critical requirement of SOS1 for tumor development and microenvironment modulation in KRAS
Baltanás FC; García-Navas R; Rodríguez-Ramos P; Calzada N; Cuesta C; Borrajo J; Fuentes-Mateos R; Olarte-San Juan A; Vidaña N; Castellano E; Santos E
Nat Commun; 2023 Sep; 14(1):5856. PubMed ID: 37730692
[TBL] [Abstract][Full Text] [Related]
2. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
3.
Chen X; Wang Y; Qu X; Bie F; Wang Y; Du J
Future Oncol; 2021 Feb; 17(5):565-579. PubMed ID: 33406903
[No Abstract] [Full Text] [Related]
4. SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity.
Zhong H; Lu W; Tang Y; Wiel C; Wei Y; Cao J; Riedlinger G; Papagiannakopoulos T; Guo JY; Bergo MO; Kang Y; Ganesan S; Sabaawy HE; Pine SR
Oncogene; 2023 Jun; 42(27):2183-2194. PubMed ID: 37258742
[TBL] [Abstract][Full Text] [Related]
5. KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Gao G; Liao W; Ma Q; Zhang B; Chen Y; Wang Y
Lung Cancer; 2020 Nov; 149():41-45. PubMed ID: 32956987
[TBL] [Abstract][Full Text] [Related]
6. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
7. Endoplasmic reticulum chaperone GRP78/BiP is critical for mutant Kras-driven lung tumorigenesis.
Rangel DF; Dubeau L; Park R; Chan P; Ha DP; Pulido MA; Mullen DJ; Vorobyova I; Zhou B; Borok Z; Offringa IA; Lee AS
Oncogene; 2021 May; 40(20):3624-3632. PubMed ID: 33931739
[TBL] [Abstract][Full Text] [Related]
8. PPDPF Promotes the Development of Mutant KRAS-Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1.
Ni QZ; Zhu B; Ji Y; Zheng QW; Liang X; Ma N; Jiang H; Zhang FK; Shang YR; Wang YK; Xu S; Zhang EB; Yuan YM; Chen TW; Yin FF; Cao HJ; Huang JY; Xia J; Ding XF; Qiu XS; Ding K; Song C; Zhou WT; Wu M; Wang K; Lui R; Lin Q; Chen W; Li ZG; Cheng SQ; Wang XF; Xie D; Li JJ
Adv Sci (Weinh); 2023 Jan; 10(2):e2202448. PubMed ID: 36453576
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
10. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
11. IκB Kinase α Is Required for Development and Progression of
Vreka M; Lilis I; Papageorgopoulou M; Giotopoulou GA; Lianou M; Giopanou I; Kanellakis NI; Spella M; Agalioti T; Armenis V; Goldmann T; Marwitz S; Yull FE; Blackwell TS; Pasparakis M; Marazioti A; Stathopoulos GT
Cancer Res; 2018 Jun; 78(11):2939-2951. PubMed ID: 29588349
[TBL] [Abstract][Full Text] [Related]
12. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
13.
Li F; Huang Q; Luster TA; Hu H; Zhang H; Ng WL; Khodadadi-Jamayran A; Wang W; Chen T; Deng J; Ranieri M; Fang Z; Pyon V; Dowling CM; Bagdatlioglu E; Almonte C; Labbe K; Silver H; Rabin AR; Jani K; Tsirigos A; Papagiannakopoulos T; Hammerman PS; Velcheti V; Freeman GJ; Qi J; Miller G; Wong KK
Cancer Discov; 2020 Feb; 10(2):270-287. PubMed ID: 31744829
[TBL] [Abstract][Full Text] [Related]
14. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
[TBL] [Abstract][Full Text] [Related]
15. Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
Alanazi M; Weng T; McLeod L; Gearing LJ; Smith JA; Kumar B; Saad MI; Jenkins BJ
Cancer Sci; 2024 Jun; 115(6):1834-1850. PubMed ID: 38594840
[TBL] [Abstract][Full Text] [Related]
16. RANKL acts an unfavorable prognostic biomarker and potential target in advanced KRAS-mutated lung adenocarcinoma.
Li HS; Liu CM; Wang Y
Thorac Cancer; 2023 May; 14(15):1368-1382. PubMed ID: 37021520
[TBL] [Abstract][Full Text] [Related]
17. Alveolar type I cells can give rise to KRAS-induced lung adenocarcinoma.
Yang M; Shen H; Flodby P; Koss MD; Bassiouni R; Liu Y; Jashashvili T; Neely A; Ogbolu E; Castillo J; Stueve TR; Mullen DJ; Ryan AL; Carpten J; Castaldi A; Wallace WD; Zhou B; Borok Z; Marconett CN
Cell Rep; 2023 Dec; 42(12):113286. PubMed ID: 37995179
[TBL] [Abstract][Full Text] [Related]
18. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma.
Best SA; Ding S; Kersbergen A; Dong X; Song JY; Xie Y; Reljic B; Li K; Vince JE; Rathi V; Wright GM; Ritchie ME; Sutherland KD
Nat Commun; 2019 Sep; 10(1):4190. PubMed ID: 31519898
[TBL] [Abstract][Full Text] [Related]
19. The kinase PLK1 promotes the development of
Kong Y; Allison DB; Zhang Q; He D; Li Y; Mao F; Li C; Li Z; Zhang Y; Wang J; Wang C; Brainson CF; Liu X
Sci Signal; 2022 Oct; 15(754):eabj4009. PubMed ID: 36194647
[TBL] [Abstract][Full Text] [Related]
20. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.
Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A
Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
